ecrin-mdr-crcClinicalNot providedEndometrial CancerLung CancerGastrointestinal NeoplasmsCervical CancerHead and Neck CancerColorectal CancerGastrointestinal CancerBladder CancerAdvanced CancerPancreatic CancerBreast NeoplasmsBreast CancerLung NeoplasmsNeoplasmsOvarian CancerProstatic NeoplasmsColon CancerGastric CancerEsophageal CancerProstate CancerOvarian NeoplasmsDigestive System NeoplasmsEndometrial CancerLung CancerGastrointestinal NeoplasmsCervical CancerGastrointestinal CancerColorectal CancerAdvanced CancerBladder CancerPancreatic CancerBreast NeoplasmsBreast CancerLung NeoplasmsNeoplasmsOvarian CancerProstatic NeoplasmsColon CancerGastric CancerEsophageal CancerProstate CancerHead And Neck CancerOvarian NeoplasmsDigestive System NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2013557United StatesNot providedStomach CancerGlioblastoma MultiformeGenitourinary CancerMotexafin gadoliniumThroat CancerRenal CancerKidney CancerMetastatic CancerRecurrent CancerECRIN MDRCompletedfalseStudy of Motexafin Gadolinium and Docetaxel for Advanced CancerThe primary purpose of this study is to evaluate the safety, side effects, and dosage for Motexafin Gadolinium given with the chemotherapy drug docetaxel to patients with advanced cancers. Secondly, tumor response to the combined treatment, drug levels in the body, and drug interactions will be evaluated.1900-01-012013557NCT00120939